Lund, Sweden, March 20, 2026. Hansa Biopharma AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa” or the “Company”) today announces that it has entered into a U.S. convertible note purchase agreement with certain funds managed by Athyrium Capital Management (“Athyrium”), comprising USD 30 million aggregate principal amount of unsecured convertible senior notes (the “Financing”). The Financing extends […]
Lund, Sweden, 13 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will be presenting at Redeye Theme Event: Commercialization in Life Science in Stockholm, at 10:15 AM CET on Friday 20 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending […]
Novo Holdings announces 2025 Annual Results Novo Holdings announced its financial results for 2025. Despite a challenging global environment, Novo Holdings has made significant progress on its Strategy 2030 during 2025 and delivered on its priorities. The Novo Holdings Investment Portfolio continued to perform well on both an absolute and relative basis, with a return […]
Lund, Sweden, 10 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at DNB Carnegie Healthcare Conference 2026 in Stockholm, at 15:10 PM EDT on Thursday 12 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending the event. […]
Lund, Sweden, 9 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be participating in a panel discussion titled “The Path to Public: Mastering Your Exit Strategy” at LSX Investival Showcase USA in Miami, at 15:15 PM EDT on Tuesday 10 March, 2026. Hansa Biopharma COO […]
